- Approval Id
- 70e5e5f94943e800
- Drug Approval Emc Name
- Ceftriaxone 1 g powder for solution for injection/infusion
- Drug Name
- Ceftriaxone 1 g powder for solution for injection/infusion
- Company Name
- AS Kalceks
- Company Address
- 71E Krustpils Str, Riga, Latvia
- Company Website
- https://www.kalceks.lv/lv/
- Company Medical Info Direct Line
- +371 67083320 / +371 66013181
- Company Medical Info Email
- kalceks@kalceks.lv
- Company Customer Care Direct Line
- +371 67083320
- Company Stock Availability
- +371 67083320 / +371 66013190
- Atc Code
- J01DD04
- Legal Category
- Prescription only medicine
- Authorisation Holder
- AS KALCEKS
Krustpils iela 71E, Rīga, LV-1057, Latvia
- Authorisation Number
- PL 47015/0030
- Authorisation Date
- 01/09/2023
- Instruction Authorisation Holder
- AS KALCEKS
Krustpils iela 71E, Rīga, LV-1057, Latvia
- Instruction Authorisation Number
- PL 47015/0030
- Instruction Authorisation Date
- 01/09/2023
- Instruction Composition
- Each vial contains 1 g of ceftriaxone (as ceftriaxone sodium).
Sodium content per vial: 83 mg (equivalent to 3.6 mmol).
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Powder for solution for injection/infusion.
Almost white or yellowish powder.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth):
| | |
| --- | --- |
| – | bacterial meningitis; |
| – | community acquired pneumonia; |
| – | hospital acquired pneumonia; |
| – | acute otitis media; |
| – | intra-abdominal infections; |
| – | complicated urinary tract infections (including pyelonephritis); |
| – | infections of bones and joints; |
| – | complicated skin and soft tissue infections; |
| – | gonorrhoea; |
| – | syphilis; |
| – | bacterial endocarditis. |
Ceftriaxone may be used:
| | |
| --- | --- |
| – | for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults; |
| – | for treatment of disseminated Lyme borreliosis (early [stage II] and late [stage III]) in adults and children including neonates from 15 days of age; |
| – | for pre-operative prophylaxis of surgical site infections; |
| – | in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; |
| – | in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. |
Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.4.2 Posology and method of administration
\*\*Posology\*\*
The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.
The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.
\*\*\*Adults and children over 12 years of age (≥ 50 kg)\*\*\*
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\\*\\*\*\* | \*\*Indications\*\* |
| 1-2 g | Once daily | Community acquired pneumonia |
| Acute exacerbations of chronic obstructive pulmonary disease |
| Intra-abdominal infections |
| Complicated urinary tract infections (including pyelonephritis) |
| 2 g | Once daily | Hospital acquired pneumonia |
| Complicated skin and soft tissue infections |
| Infections of bones and joints |
| 2-4 g | Once daily | Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| Bacterial endocarditis |
| Bacterial meningitis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
\\*\\* Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.
Indications for adults and children over 12 years of age (≥ 50 kg) that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
A single intramuscular dose of ceftriaxone 1-2 g can be given.
Limited data suggest that in cases where the patient is severely ill or previous therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 1-2 g daily for 3 days.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
2 g as a single pre-operative dose.
| | |
| --- | --- |
| - | Gonorrhoea |
500 mg as a single intramuscular dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended doses are 500 mg-1 g once daily increased to 2 g once daily for neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on limited data. National or local guidance should be taken into consideration.
| | |
| --- | --- |
| - | Disseminated Lyme borreliosis (early [stage II] and late [stage III]) |
2 g once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.
\*\*\*Paediatric population\*\*\*
\*Neonates, infants and children 15 days to 12 years of age (< 50 kg)\*
For children with body weight of 50 kg or more, the usual adult dosage should be given.
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\\*\\*\*\* | \*\*Indications\*\* |
| 50-80 mg/kg | Once daily | Intra-abdominal infections |
| Complicated urinary tract infections (including pyelonephritis) |
| Community acquired pneumonia |
| Hospital acquired pneumonia |
| 50-100 mg/kg (max 4 g) | Once daily | Complicated skin and soft tissue infections |
| Infections of bones and joints |
| Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| 80-100 mg/kg (max 4 g) | Once daily | Bacterial meningitis |
| 100 mg/kg (max 4 g) | Once daily | Bacterial endocarditis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
\\*\\* Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.
Indications for neonates, infants and children 15 days to 12 years (< 50 kg) that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
For initial treatment of acute otitis media, a single intramuscular dose of ceftriaxone 50 mg/kg can be given. Limited data suggest that in cases where the child is severely ill or initial therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 50 mg/kg daily for 3 days.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
50-80 mg/kg as a single pre-operative dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended doses are 75-100 mg/kg (max 4 g) once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.
| | |
| --- | --- |
| - | Disseminated Lyme borreliosis (early [stage II] and late [stage III]) |
50-80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.
\*Neonates 0-14 days\*
Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\*\* | \*\*Indications\*\* |
| 20-50 mg/kg | Once daily | Intra-abdominal infections |
| Complicated skin and soft tissue infections |
| Complicated urinary tract infections (including pyelonephritis) |
| Community acquired pneumonia |
| Hospital acquired pneumonia |
| Infections of bones and joints |
| Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| 50 mg/kg | Once daily | Bacterial meningitis |
| Bacterial endocarditis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
A maximum daily dose of 50 mg/kg should not be exceeded.
Indications for neonates 0-14 days that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
For initial treatment of acute otitis media, a single intramuscular dose of ceftriaxone 50 mg/kg can be given.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
20-50 mg/kg as a single pre-operative dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.
\*\*\*Duration of therapy\*\*\*
The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for 48-72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.
\*\*\*Elderly\*\*\*
The dosages recommended for adults require no modification in elderly patients provided that renal and hepatic function is satisfactory.
\*\*\*Patients with hepatic impairment\*\*\*
Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment provided renal function is not impaired.
There are no study data in patients with severe hepatic impairment (see section 5.2).
\*\*\*Patients with renal impairment\*\*\*
In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance < 10 ml/min) the ceftriaxone dosage should not exceed 2 g daily. In patients undergoing dialysis no additional supplementary dosing is required after the dialysis. Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring for safety and efficacy is advised.
\*\*\*Patients with severe hepatic and renal impairment\*\*\*
In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.
\*\*Method of administration\*\*
Intravenous, intramuscular use.
Ceftriaxone 1 g powder for solution for injection/infusion can be used for IM injection, slow IV injection and IV infusion.
\*\*\*Intramuscular use\*\*\*
Ceftriaxone can be administered as a deep intramuscular injection. Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than 1 g should be injected at one site. Doses greater than 1 g should be divided and injected into more than one site (see section 6.6). For doses greater than 2 g intravenous administration should be used. Intramuscular administration should be considered when the intravenous route is not possible or less appropriate for the patient\*.\*
As the solvent used is lidocaine, the resulting solution should never be administered intravenously (see section 4.3). The information in the Summary of Product Characteristics of lidocaine should be considered.
\*\*\*Intravenous use\*\*\*
Ceftriaxone 1 g powder for solution for injection/infusion can be administered by intravenous infusion over at least 30 minutes (preferred route of administration) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should be given over 5 minutes preferably in larger veins.
Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion. In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy (see sections 4.3 and 4.4).
Ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).
Diluents containing calcium (e.g. Ringer's solution or Hartmann's solution) should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2).
For pre-operative prophylaxis of surgical site infections, ceftriaxone should be administered 30-90 minutes prior to surgery.
The colour of the solution after reconstitution/dilution is slightly yellowish to brownish yellow, depending on the duration of storage, concentration and solvent used, but this does not affect the efficacy of the medicinal product.
For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.4.3 Contraindications
Hypersensitivity to ceftriaxone, to any other cephalosporin or to any of the excipients listed in section 6.1.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams or carbapenems).
Ceftriaxone is contraindicated in:
• premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)\\*;
• full-term neonates (up to 28 days of age):
| | | |
| --- | --- | --- |
| | – | with hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired\\*; |
| | – | if they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone calcium salt (see sections 4.4, 4.8 and 6.2). |
\\* \*In vitro\* studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.
Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine solution is used as a solvent (see section 4.4). See information in the Summary of Product Characteristics of lidocaine, especially contraindications.
Ceftriaxone solutions containing lidocaine should never be administered intravenously.4.4 Special warnings and precautions for use
\*\*Hypersensitivity reactions\*\*
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported (see section 4.8). Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction (see section 4.8). In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftriaxone is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
Severe cutaneous adverse reactions (Stevens-Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS)) which can be life-threatening or fatal, have been reported in association of ceftriaxone treatment; however, the frequency of these events is not known (see section 4.8).
\*\*Jarisch-Herxheimer reaction (JHR)\*\*
Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR) shortly after ceftriaxone treatment is started. JHR is usually a self-limiting condition or can be managed by symptomatic treatment. The antibiotic treatment should not be discontinued if such reaction occurs.
\*\*Interaction with calcium-containing products\*\*
Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term neonates aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products. \*In vitro\* studies demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.
In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solutions, even via different infusion lines or at different infusion sites. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if different infusion lines and different infusion sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).
\*\*Paediatric population\*\*
Safety and effectiveness of ceftriaxone in neonates, infants and children have been established for the dosages described under Posology and Method of Administration (see section 4.2). Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin.
Ceftriaxone is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).
\*\*Immune mediated haemolytic anaemia\*\*
An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone (see section 4.8). Severe cases of haemolytic anaemia, including fatalities, have been reported during ceftriaxone treatment in both adults and children.
If a patient develops anaemia while on ceftriaxone, the diagnosis of cephalosporin associated anaemia should be considered and ceftriaxone discontinued until the aetiology is determined.
\*\*Long-term treatment\*\*
During prolonged treatment complete blood count should be performed at regular intervals.
\*\*Colitis/Overgrowth of non-susceptible microorganisms\*\*
Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftriaxone (see section 4.8). Discontinuation of therapy with ceftriaxone and the administration of specific treatment for \*Clostridioides difficile\* should be considered. Medicinal products that inhibit peristalsis should not be given.
Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.
\*\*Encephalopathy\*\*
Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of ceftriaxone should be considered.
\*\*Severe renal and hepatic insufficiency\*\*
In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is advised (see section 4.2).
\*\*Interference with serological testing\*\*
Interference with Coombs tests may occur, as ceftriaxone may lead to false-positive test results. Ceftriaxone can also lead to false-positive test results for galactosaemia (see section 4.8).
Non-enzymatic methods for the glucose determination in urine may give false-positive results. Urine glucose determination during therapy with ceftriaxone should be done enzymatically (see section 4.8).
The presence of ceftriaxone may falsely lower measured blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.
\*\*Antibacterial spectrum\*\*
Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a single agent for the treatment of some types of infections unless the pathogen has already been confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.
\*\*Use of lidocaine\*\*
In case a lidocaine solution is used as a solvent, ceftriaxone solutions must only be used for intramuscular injection. Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use (see section 4.3). The lidocaine solution should never be administered intravenously.
\*\*Biliary lithiasis\*\*
When shadows are observed on sonograms, consideration should be given to the possibility of precipitates of ceftriaxone-calcium. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone doses of 1 g per day and above. Caution should be particularly considered in the paediatric population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely precipitates of calcium ceftriaxone have been associated with symptoms. In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit/risk assessment (see section 4.8).
\*\*Biliary stasis\*\*
Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with ceftriaxone (see section 4.8). Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor of ceftriaxone-related biliary precipitation cannot be ruled out.
\*\*Renal lithiasis\*\*
Cases of renal lithiasis have been reported, which is reversible upon discontinuation of ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in patients with history of renal lithiasis or with hypercalciuria should be considered by the physician based on specific benefit/risk assessment.
\*\*Sodium\*\*
This medicinal product contains 83 mg sodium per 1 g vial, equivalent to 4.15% of the WHO recommended maximum daily intake of 2 g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
Calcium-containing diluents, such as Ringer's solution or Hartmann's solution, should not be used to reconstitute ceftriaxone powder in vials or to further dilute a reconstituted content for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. \*In vitro\* studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).
Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug is adjusted accordingly, both during and after treatment with ceftriaxone (see section 4.8).
There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and renal function) in clinical practice should be closely adhered to in such cases.
In an \*in vitro\* study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.
There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (intravenous or oral).
In patients treated with ceftriaxone, the Coombs' test may lead to false-positive test results.
Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.
Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with ceftriaxone should be carried out enzymatically.
No impairment of renal function has been observed after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g. furosemide).
Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3). Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.
\*\*Breast-feeding\*\*
Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breast-fed infants are anticipated. However, a risk of diarrhoea and fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
Reproductive studies have shown no evidence of adverse effects on male or female fertility.4.7 Effects on ability to drive and use machines
During treatment with ceftriaxone, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8). Patients should be cautious when driving or operating machinery.4.8 Undesirable effects
The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.
Data to determine the frequency of ceftriaxone adverse drug reactions (ADRs) was derived from clinical trials.
The frequencies used in the table below are defined according to MedDRA as follows: common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) and not known (cannot be estimated from the available data).
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Common\*\* | \*\*Uncommon\*\* | \*\*Rare\*\* | \*\*Not knowna\*\* |
| Infections and infestations | | Genital fungal infection | Pseudomembranous colitisb | Superinfectionb |
| Blood and lymphatic system disorders | Eosinophilia Leucopenia Thrombocytopenia | Granulocytopenia Anaemia Coagulopathy | | Haemolytic anaemiab Agranulocytosis |
| Immune system disorders | | | | Anaphylactic shock Anaphylactic reaction Anaphylactoid reaction Hypersensitivityb Jarisch-Herxheimer reactionb |
| Nervous system disorders | | Headache Dizziness | Encephalopathy | Convulsion |
| Ear and labyrinth disorders | | | | Vertigo |
| Cardiac disorders | | | | Kounis syndrome |
| Respiratory, thoracic and mediastinal disorders | | | Bronchospasm | |
| Gastrointestinal disorders | Diarrhoeab Loose stools | Nausea Vomiting | | Pancreatitisb Stomatitis Glossitis |
| Hepatobiliary disorders | Hepatic enzyme increased | | | Gall bladder precipitationb Kernicterus Hepatitisc Hepatitis cholestaticb,c |
| Skin and subcutaneous tissue disorders | Rash | Pruritus | Urticaria | Stevens-Johnson syndromeb Toxic epidermal necrolysisb Erythema multiforme Acute generalised exanthematous pustulosis Drug reaction with eosinophilia and systemic symptoms (DRESS)b |
| Renal and urinary disorders | | | Haematuria Glycosuria | Oliguria Renal precipitation (reversible) |
| General disorders and administration site conditions | | Phlebitis Injection site pain Pyrexia | Oedema Chills | |
| Investigations | | Blood creatinine increased | | Coombs test false positiveb Galactosaemia test false positiveb Non enzymatic methods for glucose determination false positiveb |
a Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.
b See section 4.4
c Usually reversible upon discontinuation of ceftriaxone
\*\*Description of selected adverse reactions\*\*
\*\*\*Infections and infestations\*\*\*
Reports of diarrhoea following the use of ceftriaxone may be associated with \*Clostridioides difficile.\* Appropriate fluid and electrolyte management should be instituted (see section 4.4).
\*\*\*Ceftriaxone-calcium salt precipitation\*\*\*
Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).
Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. ≥ 80 mg/kg/day or total doses exceeding 10 grams) and who had other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).
Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30% in some studies. The incidence appears to be lower with slow infusion (20-30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
In overdose, the symptoms of nausea, vomiting and diarrhoea can occur. Ceftriaxone concentrations cannot be reduced by haemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdose should be symptomatic.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use, third-generation cephalosporins,
ATC code: J01DD04
\*\*Mechanism of action\*\*
Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
\*\*Resistance\*\*
Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:
| | |
| --- | --- |
| - | hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species |
| - | reduced affinity of penicillin-binding proteins for ceftriaxone |
| - | outer membrane impermeability in Gram-negative organisms |
| - | bacterial efflux pumps. |
\*\*Susceptibility testing breakpoints\*\*
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST Breakpoint tables for interpretation of MICs, Version 13.0, valid from 2023-01-01) are as follows:
| | | |
| --- | --- | --- |
| \*\*Pathogen\*\* | \*\*Dilution Test (MIC, mg/l)\*\* | |
| \*\*Susceptible\*\* | \*\*Resistant\*\* |
| \*Enterobacterales\* (indications other than meningitis) | ≤ 1 | > 2 |
| \*Enterobacterales\* (meningitis) | ≤ 1 | > 1 |
| \*Staphylococcus\* spp. | a | a |
| \*Streptococcus\* spp. (Groups A, B, C and G) | b | b |
| \*Streptococcus pneumoniae\* (indications other than meningitis) | ≤ 0.5 | > 2 |
| \*Streptococcus pneumoniae\* (meningitis) | ≤ 0.5 | > 0.5 |
| Viridans group \*Streptococci\* | ≤ 0.5 | > 0.5 |
| \*Haemophilus influenzae\* (indications other than meningitis) | ≤ 0.125 | > 0.125 |
| \*Haemophilus influenzae\* (meningitis) | ≤ 0.125 | > 0.125 |
| \*Moraxella catarrhalis\* | ≤ 1 | > 2 |
| \*Neisseria gonorrhoeae\* | ≤ 0.125 | > 0.125 |
| \*Neisseria meningitidis\* (all indications including prophylaxis) | ≤ 0.125 | > 0.125 |
| \*Kingella kingae\* | ≤ 0.06 | > 0.06 |
| Non-species related | ≤ 1 | > 2 |
a Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant \*S. aureus\* are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.
b The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.
\*\*Clinical efficacy against specific pathogens\*\*
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Specialist advice should be sought as necessary, if the local prevalence of resistance makes the use of ceftriaxone problematic for at least some types of infections.
\*\*\*\*Commonly susceptible species\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Staphylococcus aureus\* (methicillin-susceptible)£
\*Staphylococci\* coagulase-negative (methicillin-susceptible)£
\*Streptococcus pyogenes\* (Group A)
\*Streptococcus agalactiae\* (Group B)
\*Streptococcus pneumoniae\*
Viridans Group \*Streptococci\*
\*\*Gram-negative aerobes\*\*
\*Borrelia burgdorferi\*
\*Haemophilus influenzae\*
\*Haemophilus parainfluenzae\*
\*Moraxella catarrhalis\*
\*Neisseria gonorrhoea\*
\*Neisseria meningitidis\*
\*Proteus mirabilis\*
\*Providencia\* spp.
\*Treponema pallidum\*
\*\*\*\*Species for which acquired resistance may be a problem\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Staphylococcus epidermidis\*+
\*Staphylococcus haemolyticus\*+
\*Staphylococcus hominis\*+
\*\*Gram-negative aerobes\*\*
\*Citrobacter freundii\*
\*Enterobacter aerogenes\*
\*Enterobacter cloacae\*
\*Escherichia coli\*%
\*Klebsiella pneumoniae%\*
\*Klebsiella oxytoca%\*
\*Morganella morganii\*
\*Proteus vulgaris\*
\*Serratia marcescens\*
\*\*Anaerobes\*\*
\*Bacteroides\* spp.
\*Fusobacterium\* spp.
\*Peptostreptococcus\* spp.
\*Clostridium perfringens\*
\*\*\*\*Inherently resistant organisms\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Enterococcus\* spp.
\*Listeria monocytogenes\*
\*\*Gram-negative aerobes\*\*
\*Acinetobacter baumannii\*
\*Pseudomonas aeruginosa\*
\*Stenotrophomonas maltophilia\*
\*\*Anaerobes\*\*
\*Clostridioides difficile\*
\*\*Others\*\*
\*Chlamydia\* spp.
\*Chlamydophila\* spp.
\*Mycoplasma\* spp.
\*Legionella\* spp.
\*Ureaplasma urealyticum\*
£ All methicillin-resistant staphylococci are resistant to ceftriaxone.
+ Resistance rates > 50% in at least one region
% ESBL producing strains are always resistant5.2 Pharmacokinetic properties
\*\*Absorption\*\*
\*Intramuscular use\*
Following intramuscular injection, mean peak plasma ceftriaxone levels are approximately half those observed after intravenous administration of an equivalent dose. The maximum plasma concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2-3 hours after administration.
The area under the plasma concentration-time curve after intramuscular administration is equivalent to that after intravenous administration of an equivalent dose.
\*Intravenous use\*
After intravenous bolus administration of ceftriaxone 500 mg and 1 g, mean peak plasma ceftriaxone levels are approximately 120 and 200 mg/l, respectively. After intravenous infusion of ceftriaxone 500 mg, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l, respectively.
\*\*Distribution\*\*
The volume of distribution of ceftriaxone is 7-12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8-15% increase in mean peak plasma concentration (Cmax) is seen on repeated administration; steady state is reached in most cases within 48-72 hours depending on the route of administration.
\*Penetration into particular tissues\*
Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak ceftriaxone concentrations in cerebrospinal fluid (CSF) in patients with bacterial meningitis are reported to be up to 25% of plasma levels compared to 2% of plasma levels in patients with uninflamed meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).
\*Protein binding\*
Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95% at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85% at a plasma concentration of 300 mg/l).
\*\*Biotransformation\*\*
Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora.
\*\*Elimination\*\*
Plasma clearance of total ceftriaxone (bound and unbound) is 10-22 ml/min. Renal clearance is 5-12 ml/min. 50–60% of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40-50% is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours.
\*Patients with renal or hepatic impairment\*
In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.
The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total ceftriaxone.
In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.
\*Elderly\*
In elderly patients aged over 75 years the average elimination half-life is usually two to three times higher that of young adults.
\*Paediatric population\*
The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding. In children, the half-life is lower than in neonates and adults.
The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.
\*\*Linearity/non-linearity\*\*
The pharmacokinetics of ceftriaxone is non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma ceftriaxone but not for free (unbound) ceftriaxone.
\*\*Pharmacokinetic/pharmacodynamic relationship\*\*
As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with \*in vivo\* efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for individual target species (i.e. %T > MIC).5.3 Preclinical safety data
There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on ceftriaxone were not conducted.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
None.6.2 Incompatibilities
Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole, and aminoglycosides.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
In particular diluents containing calcium (e.g. Ringer's solution, Hartmann's solution) should not be used to reconstitute ceftriaxone powder in vials or to further dilute a reconstituted content for intravenous administration because a precipitate can form. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions including total parenteral nutrition (see sections 4.2, 4.3, 4.4 and 4.8).
If the treatment consists of a combination of another antibiotic and ceftriaxone, do not administer in the same syringe or infusion solution.6.3 Shelf life
2 years.
\*\*After reconstitution with lidocaine hydrochloride 10 mg/ml (1%) solution for intramuscular injection\*\*
Chemical and physical in-use stability has been demonstrated for 6 hours at 25°C.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
\*\*After reconstitution for intravenous injection\*\*
Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8°C and 12 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
\*\*After reconstitution for intravenous infusion\*\*
The reconstituted solution should be diluted immediately after reconstitution.
\*\*After dilution for intravenous infusion\*\*
Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8°C and 12 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Keep the vials in the outer carton in order to protect from light.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.6.5 Nature and contents of container
1 g powder is filled in colourless glass vial closed with grey bromobutyl rubber stopper covered with aluminium cap and dark blue plastic flip-off cap.
The vials are placed in outer cartons.
Pack sizes: 1 or 10 vials.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
For single use only.
See section 6.3 for storage conditions of the reconstituted and diluted solutions.
\*\*Compatibility with the following solutions has been demonstrated:\*\*
| | |
| --- | --- |
| - | water for injections; |
| - | lidocaine hydrochloride 10 mg/ml (1%) solution (for intramuscular injection only); |
| - | sodium chloride 9 mg/ml (0.9%) solution; |
| - | glucose 50 mg/ml (5%) solution; |
| - | glucose 100 mg/ml (10%) solution; |
| - | sodium chloride 4.5 mg/ml (0.45%) and glucose 25 mg/ml (2.5%) solution. |
\*\*Intramuscular injection\*\*
For intramuscular injection, 1 g of ceftriaxone is dissolved in 3.5 ml of 1% lidocaine hydrochloride solution.
The solution should be given by deep intramuscular injection. Doses greater than 1 g should be divided and injected into more than one site (see section 4.2).
Ceftriaxone should not be mixed with other medicines in the same syringe, except for 1% lidocaine hydrochloride solution (for intramuscular injection only).
As the solvent used is lidocaine, the resulting solution should never be administered intravenously.
\*\*Intravenous injection\*\*
For intravenous injection, 1 g of ceftriaxone is dissolved in 10 ml of water for injections. The injection is given directly into a vein or via intravenous infusion line over 5 minutes.
Concentration of ceftriaxone in the final solution for intravenous injection is 93 mg/ml.
\*\*Intravenous infusion\*\*
For intravenous infusion, 1 g of ceftriaxone is dissolved and, if necessary, further diluted with one of the compatible calcium-free solutions listed above (except lidocaine hydrochloride solution since lidocaine solutions should never be administered intravenously).
Concentration of ceftriaxone in the final solution for intravenous infusion is 48 mg/ml:
| | | |
| --- | --- | --- |
| Ceftriaxone powder | Volume of diluent | Concentration of ceftriaxone in the final solution |
| 1 g | 20 ml | 48 mg/ml |
It is recommended that the intravenous infusion line is flushed after each administration with sodium chloride 9 mg/ml (0.9%) solution for injection to ensure administration of the complete dose.
The infusion should be administered over at least 30 minutes.
In neonates, intravenous doses should be given over 60 minutes to minimize the risk of bilirubin encephalopathy (see section 4.2 for further information).
The colour of the solution after reconstitution/dilution is slightly yellowish to brownish yellow, depending on the duration of storage, concentration and solvent used, but this does not affect the efficacy of the medicinal product.
Reconstituted/diluted solutions should be visually inspected prior to use. Only clear solutions free from visible particles should be used. The reconstituted product is for single use only and any unused solution must be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each vial contains 1 g of ceftriaxone (as ceftriaxone sodium).
Sodium content per vial: 83 mg (equivalent to 3.6 mmol).
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Powder for solution for injection/infusion.
Almost white or yellowish powder.
## Clinical Particulars
4.1 Therapeutic indications
Ceftriaxone is indicated for the treatment of the following infections in adults and children including term neonates (from birth):
| | |
| --- | --- |
| – | bacterial meningitis; |
| – | community acquired pneumonia; |
| – | hospital acquired pneumonia; |
| – | acute otitis media; |
| – | intra-abdominal infections; |
| – | complicated urinary tract infections (including pyelonephritis); |
| – | infections of bones and joints; |
| – | complicated skin and soft tissue infections; |
| – | gonorrhoea; |
| – | syphilis; |
| – | bacterial endocarditis. |
Ceftriaxone may be used:
| | |
| --- | --- |
| – | for treatment of acute exacerbations of chronic obstructive pulmonary disease in adults; |
| – | for treatment of disseminated Lyme borreliosis (early [stage II] and late [stage III]) in adults and children including neonates from 15 days of age; |
| – | for pre-operative prophylaxis of surgical site infections; |
| – | in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection; |
| – | in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. |
Ceftriaxone should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).
Consideration should be given to official guidelines on the appropriate use of antibacterial agents.4.2 Posology and method of administration
\*\*Posology\*\*
The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato-renal function of the patient.
The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.
\*\*\*Adults and children over 12 years of age (≥ 50 kg)\*\*\*
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\\*\\*\*\* | \*\*Indications\*\* |
| 1-2 g | Once daily | Community acquired pneumonia |
| Acute exacerbations of chronic obstructive pulmonary disease |
| Intra-abdominal infections |
| Complicated urinary tract infections (including pyelonephritis) |
| 2 g | Once daily | Hospital acquired pneumonia |
| Complicated skin and soft tissue infections |
| Infections of bones and joints |
| 2-4 g | Once daily | Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| Bacterial endocarditis |
| Bacterial meningitis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
\\*\\* Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.
Indications for adults and children over 12 years of age (≥ 50 kg) that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
A single intramuscular dose of ceftriaxone 1-2 g can be given.
Limited data suggest that in cases where the patient is severely ill or previous therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 1-2 g daily for 3 days.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
2 g as a single pre-operative dose.
| | |
| --- | --- |
| - | Gonorrhoea |
500 mg as a single intramuscular dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended doses are 500 mg-1 g once daily increased to 2 g once daily for neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on limited data. National or local guidance should be taken into consideration.
| | |
| --- | --- |
| - | Disseminated Lyme borreliosis (early [stage II] and late [stage III]) |
2 g once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.
\*\*\*Paediatric population\*\*\*
\*Neonates, infants and children 15 days to 12 years of age (< 50 kg)\*
For children with body weight of 50 kg or more, the usual adult dosage should be given.
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\\*\\*\*\* | \*\*Indications\*\* |
| 50-80 mg/kg | Once daily | Intra-abdominal infections |
| Complicated urinary tract infections (including pyelonephritis) |
| Community acquired pneumonia |
| Hospital acquired pneumonia |
| 50-100 mg/kg (max 4 g) | Once daily | Complicated skin and soft tissue infections |
| Infections of bones and joints |
| Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| 80-100 mg/kg (max 4 g) | Once daily | Bacterial meningitis |
| 100 mg/kg (max 4 g) | Once daily | Bacterial endocarditis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
\\*\\* Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.
Indications for neonates, infants and children 15 days to 12 years (< 50 kg) that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
For initial treatment of acute otitis media, a single intramuscular dose of ceftriaxone 50 mg/kg can be given. Limited data suggest that in cases where the child is severely ill or initial therapy has failed, ceftriaxone may be effective when given as an intramuscular dose of 50 mg/kg daily for 3 days.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
50-80 mg/kg as a single pre-operative dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended doses are 75-100 mg/kg (max 4 g) once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.
| | |
| --- | --- |
| - | Disseminated Lyme borreliosis (early [stage II] and late [stage III]) |
50-80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.
\*Neonates 0-14 days\*
Ceftriaxone is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).
| | | |
| --- | --- | --- |
| \*\*Ceftriaxone dosage\\*\*\* | \*\*Treatment frequency\*\* | \*\*Indications\*\* |
| 20-50 mg/kg | Once daily | Intra-abdominal infections |
| Complicated skin and soft tissue infections |
| Complicated urinary tract infections (including pyelonephritis) |
| Community acquired pneumonia |
| Hospital acquired pneumonia |
| Infections of bones and joints |
| Management of neutropenic patients with fever that is suspected to be due to a bacterial infection |
| 50 mg/kg | Once daily | Bacterial meningitis |
| Bacterial endocarditis |
\\* In documented bacteraemia, the higher end of the recommended dose range should be considered.
A maximum daily dose of 50 mg/kg should not be exceeded.
Indications for neonates 0-14 days that require specific dosage schedules:
| | |
| --- | --- |
| - | Acute otitis media |
For initial treatment of acute otitis media, a single intramuscular dose of ceftriaxone 50 mg/kg can be given.
| | |
| --- | --- |
| - | Pre-operative prophylaxis of surgical site infections |
20-50 mg/kg as a single pre-operative dose.
| | |
| --- | --- |
| - | Syphilis |
The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.
\*\*\*Duration of therapy\*\*\*
The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for 48-72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.
\*\*\*Elderly\*\*\*
The dosages recommended for adults require no modification in elderly patients provided that renal and hepatic function is satisfactory.
\*\*\*Patients with hepatic impairment\*\*\*
Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment provided renal function is not impaired.
There are no study data in patients with severe hepatic impairment (see section 5.2).
\*\*\*Patients with renal impairment\*\*\*
In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance < 10 ml/min) the ceftriaxone dosage should not exceed 2 g daily. In patients undergoing dialysis no additional supplementary dosing is required after the dialysis. Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring for safety and efficacy is advised.
\*\*\*Patients with severe hepatic and renal impairment\*\*\*
In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.
\*\*Method of administration\*\*
Intravenous, intramuscular use.
Ceftriaxone 1 g powder for solution for injection/infusion can be used for IM injection, slow IV injection and IV infusion.
\*\*\*Intramuscular use\*\*\*
Ceftriaxone can be administered as a deep intramuscular injection. Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than 1 g should be injected at one site. Doses greater than 1 g should be divided and injected into more than one site (see section 6.6). For doses greater than 2 g intravenous administration should be used. Intramuscular administration should be considered when the intravenous route is not possible or less appropriate for the patient\*.\*
As the solvent used is lidocaine, the resulting solution should never be administered intravenously (see section 4.3). The information in the Summary of Product Characteristics of lidocaine should be considered.
\*\*\*Intravenous use\*\*\*
Ceftriaxone 1 g powder for solution for injection/infusion can be administered by intravenous infusion over at least 30 minutes (preferred route of administration) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should be given over 5 minutes preferably in larger veins.
Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion. In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy (see sections 4.3 and 4.4).
Ceftriaxone is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).
Diluents containing calcium (e.g. Ringer's solution or Hartmann's solution) should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2).
For pre-operative prophylaxis of surgical site infections, ceftriaxone should be administered 30-90 minutes prior to surgery.
The colour of the solution after reconstitution/dilution is slightly yellowish to brownish yellow, depending on the duration of storage, concentration and solvent used, but this does not affect the efficacy of the medicinal product.
For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.4.3 Contraindications
Hypersensitivity to ceftriaxone, to any other cephalosporin or to any of the excipients listed in section 6.1.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams or carbapenems).
Ceftriaxone is contraindicated in:
• premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)\\*;
• full-term neonates (up to 28 days of age):
| | | |
| --- | --- | --- |
| | – | with hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired\\*; |
| | – | if they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone calcium salt (see sections 4.4, 4.8 and 6.2). |
\\* \*In vitro\* studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.
Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine solution is used as a solvent (see section 4.4). See information in the Summary of Product Characteristics of lidocaine, especially contraindications.
Ceftriaxone solutions containing lidocaine should never be administered intravenously.4.4 Special warnings and precautions for use
\*\*Hypersensitivity reactions\*\*
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported (see section 4.8). Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction (see section 4.8). In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftriaxone is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
Severe cutaneous adverse reactions (Stevens-Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms (DRESS)) which can be life-threatening or fatal, have been reported in association of ceftriaxone treatment; however, the frequency of these events is not known (see section 4.8).
\*\*Jarisch-Herxheimer reaction (JHR)\*\*
Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR) shortly after ceftriaxone treatment is started. JHR is usually a self-limiting condition or can be managed by symptomatic treatment. The antibiotic treatment should not be discontinued if such reaction occurs.
\*\*Interaction with calcium-containing products\*\*
Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term neonates aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products. \*In vitro\* studies demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.
In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solutions, even via different infusion lines or at different infusion sites. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if different infusion lines and different infusion sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).
\*\*Paediatric population\*\*
Safety and effectiveness of ceftriaxone in neonates, infants and children have been established for the dosages described under Posology and Method of Administration (see section 4.2). Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin.
Ceftriaxone is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).
\*\*Immune mediated haemolytic anaemia\*\*
An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including ceftriaxone (see section 4.8). Severe cases of haemolytic anaemia, including fatalities, have been reported during ceftriaxone treatment in both adults and children.
If a patient develops anaemia while on ceftriaxone, the diagnosis of cephalosporin associated anaemia should be considered and ceftriaxone discontinued until the aetiology is determined.
\*\*Long-term treatment\*\*
During prolonged treatment complete blood count should be performed at regular intervals.
\*\*Colitis/Overgrowth of non-susceptible microorganisms\*\*
Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftriaxone (see section 4.8). Discontinuation of therapy with ceftriaxone and the administration of specific treatment for \*Clostridioides difficile\* should be considered. Medicinal products that inhibit peristalsis should not be given.
Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.
\*\*Encephalopathy\*\*
Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of ceftriaxone should be considered.
\*\*Severe renal and hepatic insufficiency\*\*
In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is advised (see section 4.2).
\*\*Interference with serological testing\*\*
Interference with Coombs tests may occur, as ceftriaxone may lead to false-positive test results. Ceftriaxone can also lead to false-positive test results for galactosaemia (see section 4.8).
Non-enzymatic methods for the glucose determination in urine may give false-positive results. Urine glucose determination during therapy with ceftriaxone should be done enzymatically (see section 4.8).
The presence of ceftriaxone may falsely lower measured blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.
\*\*Antibacterial spectrum\*\*
Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a single agent for the treatment of some types of infections unless the pathogen has already been confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.
\*\*Use of lidocaine\*\*
In case a lidocaine solution is used as a solvent, ceftriaxone solutions must only be used for intramuscular injection. Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use (see section 4.3). The lidocaine solution should never be administered intravenously.
\*\*Biliary lithiasis\*\*
When shadows are observed on sonograms, consideration should be given to the possibility of precipitates of ceftriaxone-calcium. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone doses of 1 g per day and above. Caution should be particularly considered in the paediatric population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely precipitates of calcium ceftriaxone have been associated with symptoms. In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit/risk assessment (see section 4.8).
\*\*Biliary stasis\*\*
Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with ceftriaxone (see section 4.8). Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor of ceftriaxone-related biliary precipitation cannot be ruled out.
\*\*Renal lithiasis\*\*
Cases of renal lithiasis have been reported, which is reversible upon discontinuation of ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in patients with history of renal lithiasis or with hypercalciuria should be considered by the physician based on specific benefit/risk assessment.
\*\*Sodium\*\*
This medicinal product contains 83 mg sodium per 1 g vial, equivalent to 4.15% of the WHO recommended maximum daily intake of 2 g sodium for an adult.4.5 Interaction with other medicinal products and other forms of interaction
Calcium-containing diluents, such as Ringer's solution or Hartmann's solution, should not be used to reconstitute ceftriaxone powder in vials or to further dilute a reconstituted content for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. \*In vitro\* studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).
Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug is adjusted accordingly, both during and after treatment with ceftriaxone (see section 4.8).
There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and renal function) in clinical practice should be closely adhered to in such cases.
In an \*in vitro\* study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.
There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (intravenous or oral).
In patients treated with ceftriaxone, the Coombs' test may lead to false-positive test results.
Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.
Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with ceftriaxone should be carried out enzymatically.
No impairment of renal function has been observed after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g. furosemide).
Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3). Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.
\*\*Breast-feeding\*\*
Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breast-fed infants are anticipated. However, a risk of diarrhoea and fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
\*\*Fertility\*\*
Reproductive studies have shown no evidence of adverse effects on male or female fertility.4.7 Effects on ability to drive and use machines
During treatment with ceftriaxone, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8). Patients should be cautious when driving or operating machinery.4.8 Undesirable effects
The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.
Data to determine the frequency of ceftriaxone adverse drug reactions (ADRs) was derived from clinical trials.
The frequencies used in the table below are defined according to MedDRA as follows: common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) and not known (cannot be estimated from the available data).
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Common\*\* | \*\*Uncommon\*\* | \*\*Rare\*\* | \*\*Not knowna\*\* |
| Infections and infestations | | Genital fungal infection | Pseudomembranous colitisb | Superinfectionb |
| Blood and lymphatic system disorders | Eosinophilia Leucopenia Thrombocytopenia | Granulocytopenia Anaemia Coagulopathy | | Haemolytic anaemiab Agranulocytosis |
| Immune system disorders | | | | Anaphylactic shock Anaphylactic reaction Anaphylactoid reaction Hypersensitivityb Jarisch-Herxheimer reactionb |
| Nervous system disorders | | Headache Dizziness | Encephalopathy | Convulsion |
| Ear and labyrinth disorders | | | | Vertigo |
| Cardiac disorders | | | | Kounis syndrome |
| Respiratory, thoracic and mediastinal disorders | | | Bronchospasm | |
| Gastrointestinal disorders | Diarrhoeab Loose stools | Nausea Vomiting | | Pancreatitisb Stomatitis Glossitis |
| Hepatobiliary disorders | Hepatic enzyme increased | | | Gall bladder precipitationb Kernicterus Hepatitisc Hepatitis cholestaticb,c |
| Skin and subcutaneous tissue disorders | Rash | Pruritus | Urticaria | Stevens-Johnson syndromeb Toxic epidermal necrolysisb Erythema multiforme Acute generalised exanthematous pustulosis Drug reaction with eosinophilia and systemic symptoms (DRESS)b |
| Renal and urinary disorders | | | Haematuria Glycosuria | Oliguria Renal precipitation (reversible) |
| General disorders and administration site conditions | | Phlebitis Injection site pain Pyrexia | Oedema Chills | |
| Investigations | | Blood creatinine increased | | Coombs test false positiveb Galactosaemia test false positiveb Non enzymatic methods for glucose determination false positiveb |
a Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorised as not known.
b See section 4.4
c Usually reversible upon discontinuation of ceftriaxone
\*\*Description of selected adverse reactions\*\*
\*\*\*Infections and infestations\*\*\*
Reports of diarrhoea following the use of ceftriaxone may be associated with \*Clostridioides difficile.\* Appropriate fluid and electrolyte management should be instituted (see section 4.4).
\*\*\*Ceftriaxone-calcium salt precipitation\*\*\*
Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged < 28 days) who had been treated with intravenous ceftriaxone and calcium. Precipitations of ceftriaxone calcium salt have been observed in lung and kidneys post-mortem. The high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).
Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. ≥ 80 mg/kg/day or total doses exceeding 10 grams) and who had other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).
Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30% in some studies. The incidence appears to be lower with slow infusion (20-30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases. Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
In overdose, the symptoms of nausea, vomiting and diarrhoea can occur. Ceftriaxone concentrations cannot be reduced by haemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdose should be symptomatic.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antibacterials for systemic use, third-generation cephalosporins,
ATC code: J01DD04
\*\*Mechanism of action\*\*
Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.
\*\*Resistance\*\*
Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:
| | |
| --- | --- |
| - | hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species |
| - | reduced affinity of penicillin-binding proteins for ceftriaxone |
| - | outer membrane impermeability in Gram-negative organisms |
| - | bacterial efflux pumps. |
\*\*Susceptibility testing breakpoints\*\*
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST Breakpoint tables for interpretation of MICs, Version 13.0, valid from 2023-01-01) are as follows:
| | | |
| --- | --- | --- |
| \*\*Pathogen\*\* | \*\*Dilution Test (MIC, mg/l)\*\* | |
| \*\*Susceptible\*\* | \*\*Resistant\*\* |
| \*Enterobacterales\* (indications other than meningitis) | ≤ 1 | > 2 |
| \*Enterobacterales\* (meningitis) | ≤ 1 | > 1 |
| \*Staphylococcus\* spp. | a | a |
| \*Streptococcus\* spp. (Groups A, B, C and G) | b | b |
| \*Streptococcus pneumoniae\* (indications other than meningitis) | ≤ 0.5 | > 2 |
| \*Streptococcus pneumoniae\* (meningitis) | ≤ 0.5 | > 0.5 |
| Viridans group \*Streptococci\* | ≤ 0.5 | > 0.5 |
| \*Haemophilus influenzae\* (indications other than meningitis) | ≤ 0.125 | > 0.125 |
| \*Haemophilus influenzae\* (meningitis) | ≤ 0.125 | > 0.125 |
| \*Moraxella catarrhalis\* | ≤ 1 | > 2 |
| \*Neisseria gonorrhoeae\* | ≤ 0.125 | > 0.125 |
| \*Neisseria meningitidis\* (all indications including prophylaxis) | ≤ 0.125 | > 0.125 |
| \*Kingella kingae\* | ≤ 0.06 | > 0.06 |
| Non-species related | ≤ 1 | > 2 |
a Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant \*S. aureus\* are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.
b The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.
\*\*Clinical efficacy against specific pathogens\*\*
The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. Specialist advice should be sought as necessary, if the local prevalence of resistance makes the use of ceftriaxone problematic for at least some types of infections.
\*\*\*\*Commonly susceptible species\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Staphylococcus aureus\* (methicillin-susceptible)£
\*Staphylococci\* coagulase-negative (methicillin-susceptible)£
\*Streptococcus pyogenes\* (Group A)
\*Streptococcus agalactiae\* (Group B)
\*Streptococcus pneumoniae\*
Viridans Group \*Streptococci\*
\*\*Gram-negative aerobes\*\*
\*Borrelia burgdorferi\*
\*Haemophilus influenzae\*
\*Haemophilus parainfluenzae\*
\*Moraxella catarrhalis\*
\*Neisseria gonorrhoea\*
\*Neisseria meningitidis\*
\*Proteus mirabilis\*
\*Providencia\* spp.
\*Treponema pallidum\*
\*\*\*\*Species for which acquired resistance may be a problem\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Staphylococcus epidermidis\*+
\*Staphylococcus haemolyticus\*+
\*Staphylococcus hominis\*+
\*\*Gram-negative aerobes\*\*
\*Citrobacter freundii\*
\*Enterobacter aerogenes\*
\*Enterobacter cloacae\*
\*Escherichia coli\*%
\*Klebsiella pneumoniae%\*
\*Klebsiella oxytoca%\*
\*Morganella morganii\*
\*Proteus vulgaris\*
\*Serratia marcescens\*
\*\*Anaerobes\*\*
\*Bacteroides\* spp.
\*Fusobacterium\* spp.
\*Peptostreptococcus\* spp.
\*Clostridium perfringens\*
\*\*\*\*Inherently resistant organisms\*\*\*\*
\*\*Gram-positive aerobes\*\*
\*Enterococcus\* spp.
\*Listeria monocytogenes\*
\*\*Gram-negative aerobes\*\*
\*Acinetobacter baumannii\*
\*Pseudomonas aeruginosa\*
\*Stenotrophomonas maltophilia\*
\*\*Anaerobes\*\*
\*Clostridioides difficile\*
\*\*Others\*\*
\*Chlamydia\* spp.
\*Chlamydophila\* spp.
\*Mycoplasma\* spp.
\*Legionella\* spp.
\*Ureaplasma urealyticum\*
£ All methicillin-resistant staphylococci are resistant to ceftriaxone.
+ Resistance rates > 50% in at least one region
% ESBL producing strains are always resistant5.2 Pharmacokinetic properties
\*\*Absorption\*\*
\*Intramuscular use\*
Following intramuscular injection, mean peak plasma ceftriaxone levels are approximately half those observed after intravenous administration of an equivalent dose. The maximum plasma concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2-3 hours after administration.
The area under the plasma concentration-time curve after intramuscular administration is equivalent to that after intravenous administration of an equivalent dose.
\*Intravenous use\*
After intravenous bolus administration of ceftriaxone 500 mg and 1 g, mean peak plasma ceftriaxone levels are approximately 120 and 200 mg/l, respectively. After intravenous infusion of ceftriaxone 500 mg, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l, respectively.
\*\*Distribution\*\*
The volume of distribution of ceftriaxone is 7-12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8-15% increase in mean peak plasma concentration (Cmax) is seen on repeated administration; steady state is reached in most cases within 48-72 hours depending on the route of administration.
\*Penetration into particular tissues\*
Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak ceftriaxone concentrations in cerebrospinal fluid (CSF) in patients with bacterial meningitis are reported to be up to 25% of plasma levels compared to 2% of plasma levels in patients with uninflamed meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).
\*Protein binding\*
Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95% at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85% at a plasma concentration of 300 mg/l).
\*\*Biotransformation\*\*
Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora.
\*\*Elimination\*\*
Plasma clearance of total ceftriaxone (bound and unbound) is 10-22 ml/min. Renal clearance is 5-12 ml/min. 50–60% of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40-50% is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours.
\*Patients with renal or hepatic impairment\*
In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.
The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total ceftriaxone.
In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.
\*Elderly\*
In elderly patients aged over 75 years the average elimination half-life is usually two to three times higher that of young adults.
\*Paediatric population\*
The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding. In children, the half-life is lower than in neonates and adults.
The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.
\*\*Linearity/non-linearity\*\*
The pharmacokinetics of ceftriaxone is non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma ceftriaxone but not for free (unbound) ceftriaxone.
\*\*Pharmacokinetic/pharmacodynamic relationship\*\*
As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with \*in vivo\* efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for individual target species (i.e. %T > MIC).5.3 Preclinical safety data
There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible. Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on ceftriaxone were not conducted.
## Pharmaceutical Particulars
6.1 List of excipients
None.6.2 Incompatibilities
Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole, and aminoglycosides.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
In particular diluents containing calcium (e.g. Ringer's solution, Hartmann's solution) should not be used to reconstitute ceftriaxone powder in vials or to further dilute a reconstituted content for intravenous administration because a precipitate can form. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions including total parenteral nutrition (see sections 4.2, 4.3, 4.4 and 4.8).
If the treatment consists of a combination of another antibiotic and ceftriaxone, do not administer in the same syringe or infusion solution.6.3 Shelf life
2 years.
\*\*After reconstitution with lidocaine hydrochloride 10 mg/ml (1%) solution for intramuscular injection\*\*
Chemical and physical in-use stability has been demonstrated for 6 hours at 25°C.
From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
\*\*After reconstitution for intravenous injection\*\*
Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8°C and 12 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution has taken place in controlled and validated aseptic conditions.
\*\*After reconstitution for intravenous infusion\*\*
The reconstituted solution should be diluted immediately after reconstitution.
\*\*After dilution for intravenous infusion\*\*
Chemical and physical in-use stability has been demonstrated for 48 hours at 2 to 8°C and 12 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions.
Keep the vials in the outer carton in order to protect from light.
For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.6.5 Nature and contents of container
1 g powder is filled in colourless glass vial closed with grey bromobutyl rubber stopper covered with aluminium cap and dark blue plastic flip-off cap.
The vials are placed in outer cartons.
Pack sizes: 1 or 10 vials.
Not all pack sizes may be marketed.6.6 Special precautions for disposal and other handling
For single use only.
See section 6.3 for storage conditions of the reconstituted and diluted solutions.
\*\*Compatibility with the following solutions has been demonstrated:\*\*
| | |
| --- | --- |
| - | water for injections; |
| - | lidocaine hydrochloride 10 mg/ml (1%) solution (for intramuscular injection only); |
| - | sodium chloride 9 mg/ml (0.9%) solution; |
| - | glucose 50 mg/ml (5%) solution; |
| - | glucose 100 mg/ml (10%) solution; |
| - | sodium chloride 4.5 mg/ml (0.45%) and glucose 25 mg/ml (2.5%) solution. |
\*\*Intramuscular injection\*\*
For intramuscular injection, 1 g of ceftriaxone is dissolved in 3.5 ml of 1% lidocaine hydrochloride solution.
The solution should be given by deep intramuscular injection. Doses greater than 1 g should be divided and injected into more than one site (see section 4.2).
Ceftriaxone should not be mixed with other medicines in the same syringe, except for 1% lidocaine hydrochloride solution (for intramuscular injection only).
As the solvent used is lidocaine, the resulting solution should never be administered intravenously.
\*\*Intravenous injection\*\*
For intravenous injection, 1 g of ceftriaxone is dissolved in 10 ml of water for injections. The injection is given directly into a vein or via intravenous infusion line over 5 minutes.
Concentration of ceftriaxone in the final solution for intravenous injection is 93 mg/ml.
\*\*Intravenous infusion\*\*
For intravenous infusion, 1 g of ceftriaxone is dissolved and, if necessary, further diluted with one of the compatible calcium-free solutions listed above (except lidocaine hydrochloride solution since lidocaine solutions should never be administered intravenously).
Concentration of ceftriaxone in the final solution for intravenous infusion is 48 mg/ml:
| | | |
| --- | --- | --- |
| Ceftriaxone powder | Volume of diluent | Concentration of ceftriaxone in the final solution |
| 1 g | 20 ml | 48 mg/ml |
It is recommended that the intravenous infusion line is flushed after each administration with sodium chloride 9 mg/ml (0.9%) solution for injection to ensure administration of the complete dose.
The infusion should be administered over at least 30 minutes.
In neonates, intravenous doses should be given over 60 minutes to minimize the risk of bilirubin encephalopathy (see section 4.2 for further information).
The colour of the solution after reconstitution/dilution is slightly yellowish to brownish yellow, depending on the duration of storage, concentration and solvent used, but this does not affect the efficacy of the medicinal product.
Reconstituted/diluted solutions should be visually inspected prior to use. Only clear solutions free from visible particles should be used. The reconstituted product is for single use only and any unused solution must be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
